Molecular study of TP53 Gene in Iraqi Women suffered with Breast Cancer
Abstract views: 12
/ 
PDF downloads: 5
Keywords:
TP53 Gene, ARMS-PCR, RFLP-PCR, Polymorphism and Breast CarcinomaAbstract
Nearly 75% of malignancies have been associated with P53 protein failure, which typically
results from TP53 gene mutation. TP53 is activated in response to DNA damage and hypoxia and repairs
damaged DNA, which has an impact on cell aging and apoptosis. These actions are essential for tumor
suppression in addition to modifying cellular responses associated with cell cycle regulation, which is a
critical component of tumor suppression. Between September and November 2021, (96) referrals for
female patients between the ages of 35 and 45 were sent to the Alternative Nuclear Medicine and
Oncology Hospital in Mosul. The samples were split into two groups, one containing 71 women with
breast cancer and the other 25 healthy women. This study identified the polymorphisms of TP53 in codon
249 for exon 7 and (rs1042522) in exon 4, as well as the nucleotide sequences of the amplified parts using
DNA sequencing technology, coupled with a variety of physiological variables and blood components.
For instance, the levels of hemoglobin, urea, creatinine, red blood cells, white blood cells, and platelets.
Exons 3, 4, and 6 had varied numbers of nucleotides, according to the findings of a sequencing test on the
gene's amplified exons, however exon 5 had no change in nucleotides. Additionally, an unique genotype
of the TP53 gene with the GeneBank identifying number of LC682536.1 was discovered in the city of
Mosul at the NCBI global gene site. A novel phenotype of the P53 tumor suppressor protein was also
found in Mosul, and it was given the identification number GenBank: BDF83325.1. According to the
study, the ratio between the levels of CA15-3 in patients and healthy controls was 23 (U/ml), while the
patients' levels of urea were 38.2 (mg/dl). According to these findings, both the levels of urea and
creatinine in the patients' blood plasma and the levels of CA15-3 in the blood plasma of breast cancer
patients were significantly lower than those of healthy controls. The current investigation found that the
total number of WBC, RBC, PL, and HB levels in the blood of breast cancer patients had dropped
dramatically.
Downloads
References
Mattiuzzi, C. and Lippi, G. (2019). Current cancer epidemiology. Journal of epidemiology and global health, 9(4): 217.
Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D. M. and et al. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer., 149(4): 778-789.
Ahmad, A. (2019). Breast cancer statistics: recent trends. Breast Cancer Metastasis and Drug Resistance., 1-7.
Momenimovahed, Z. and Salehiniya, H. (2019). Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer: Targets and Therapy., 11: 151.
Takahashi, C. and Kato, J. Y. (2022). Targeting Abnormal Cell Cycle in Cancer: A Preface to the Special Issue. Onco., 2(1): 34-35.
Liu, J.; Peng, Y. and Wei, W. (2021). Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends in cell biology.
Koff, J. L.; Ramachandiran, S. and Bernal-Mizrachi, L. (2015). A time to kill: targeting apoptosis in cancer. International journal of molecular sciences., 16(2): 2942-2955.
Mohammad, R. M.; Muqbil, I.; Lowe, L.; Yedjou, C. and et al. (2015). Broad targeting of resistance to apoptosis in cancer. Seminars in cancer biology. Academic Press., 35: 78-103.
Sokoll, L. J. and Chan, D. W. (2020). Tumor markers. Contemporary Practice in Clinical Chemistry. Academic Press., 779-793
Nagpal, M.; Singh, S.; Singh, P.; Chauhan, P. and Zaidi, M. A. (2016). Tumor markers: A diagnostic tool. National journal of maxillofacial surgery., 7(1): 17.
Levine, A. J. and Puzio-Kuter, A. M. (2010). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science., 330(6009): 1340-1344.
Shortt, J. and Johnstone, R. W. (2012). Oncogenes in cell survival and cell death. Cold Spring Harbor perspectives in biology., 4(12): 009829.
Zhao, M.; Sun, J. and Zhao, Z. (2013). TSGene: a web resource for tumor suppressor genes. Nucleic acids research., 41(1): 970-976.
Aubrey, B. J.; Strasser, A. and Kelly, G. L. (2016). Tumor-suppressor functions of the TP53 pathway. Cold Spring Harbor perspectives in medicine., 6(5): 026062.
Olivier, M.; Hollstein, M. and Hainaut, P. (2010). TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor perspectives in biology., 2(1): 001008.
Iranpur, V. and Esmailizadeh, A. (2010) Rapid Extraction of High Quality DNA from Whole Blood Stored at 4ºC for Long Period. Department of Animal Science, Faculty of Agriculture, Shahrekord University, Shahrekord, Iran. www. Protocol-online.org.
Vijayaraman, K. P.; Veluchamy, M.; Murugesan, P.; Shanmugiah, K. P. and Kasi, P. D. (2012). p53 exon 4 (codon 72) polymorphism and exon 7 (codon 249) mutation in breast cancer patients in southern region (Madurai) of Tamil Nadu. Asian Pacific Journal of Cancer Prevention., 13(2): 511-516.
Asadi, M.; Shanehbandi, D.; Zarintan, A.; Pedram, N. and et al. (2017). TP53 Gene Pro72Arg (rs1042522) single nucleotide polymorphism as not a risk factor for colorectal cancer in the Iranian Azari population. Asian Pacific journal of cancer prevention: APJCP., 18(12): 3423.
Wang, Z.; Strasser, A. and Kelly, G. L. (2022). Should mutant TP53 be targeted for cancer therapy?. Cell Death and Differentiation., 29(5): 911-920.
Levine, A. J. (2019). Targeting therapies for the p53 protein in cancer treatments. Annual Review of Cancer Biology., 3: 21-34.
Bouaoun, L.; Sonkin, D.; Ardin, M.; Hollstein, M. and et al. (2016). TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Human mutation., 37(9): 865-876.
Mishra, P. A.; Chaudhari, H. R.; Desai, J. S. and Khan, U. N. (2013). p53: An overview. Internafional Journal of Pharmacy and Pharmaceufical Sciences., 5: 59-65.
Dahabreh, I. J.; Schmid, C. H.; Lau, J.; Varvarigou, V. and et al. (2013). Genotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancer. American journal of epidemiology., 177(12): 1317-1325.
Doffe, F.; Carbonnier, V.; Tissier, M.; Leroy, B. and et al. (2021). Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. Cell Death and Differentiation., 28(5): 1477-1492.
Kim, M. P. and Lozano, G. (2018). Mutant p53 partners in crime. Cell Death and Differentiation., 25(1): 161-168.
